Is Semaglutide on the NHS for Weight Loss? The Real Picture

The myth: your GP can prescribe Wegovy if your BMI is high enough

This is the most common misunderstanding, and it matters. Many people assume that because semaglutide is NICE-recommended, a GP can simply write a Wegovy prescription once a BMI threshold is crossed. That is not how the current guidance works.

NICE's appraisal TA875, published in March 2023, recommends semaglutide for weight management only when used within a specialist weight management service that provides multidisciplinary support, including dietary, psychological and physical activity input alongside the medicine. It also caps NHS treatment at a maximum of two years. If a patient loses less than 5% of their body weight after six months at the maintenance dose, NICE guidance says continuation should be reviewed. These are not conditions that a standard GP appointment can easily satisfy, which is why access runs through specialist services rather than routine primary care.

The eligibility thresholds add another layer. NICE TA875 sets a starting BMI of 35 or above, with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, obstructive sleep apnoea or cardiovascular disease. For adults from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the thresholds are typically 2.5 kg/m² lower. A BMI of 34.9 with no weight-related conditions falls outside the criteria entirely, regardless of how much weight someone wants to lose. You can read the full NICE recommendation at NICE TA875 on the NICE website.

What the NHS actually funds, and the waiting-list reality

The NHS funds Wegovy through specialist weight management services, which are commissioned in waves across England. Demand has far outpaced capacity. In practice, many people who qualify on paper join a waiting list that stretches months, sometimes longer, before they are seen, let alone start treatment. The picture differs across the devolved nations; Scotland, Wales and Northern Ireland operate under different commissioning arrangements, so eligibility and wait times vary.

It is also worth being clear on what is NOT funded. Ozempic is semaglutide prescribed for type 2 diabetes, not weight management, and using it off-label for weight loss is not an NHS route. For a broader look at how semaglutide fits into NHS weight-loss pathways, that page sets out the commissioning picture in more detail. The NHS weight-loss medicine landscape also includes tirzepatide (Mounjaro), which has its own phased NHS rollout under a separate NICE appraisal.

For people who do not meet the NHS criteria, or who cannot wait, a private prescription from a regulated pharmacy is the legal alternative, covering everything from how to find a legitimate provider to what the assessment process involves. That requires a clinical assessment by a prescriber, the medicine remains prescription-only regardless of the route.

The private prescription route and what to look for

Private online pharmacies can prescribe Wegovy to adults with a BMI of 30 or above (or 27 and above with a qualifying weight-related condition) following a clinical consultation. The licensed eligibility criteria are broader than the NHS's commissioned criteria, which is why some people who don't qualify for the NHS route can still access treatment privately after a prescriber assessment.

Before choosing a provider, it is worth checking that the pharmacy is registered with the General Pharmaceutical Council. You can verify any online pharmacy directly at the GPhC register. A legitimate provider will always require a consultation and a prescription; any seller offering semaglutide without a clinical assessment is operating outside the law. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online without proper oversight, fake pens have caused serious harm.

At nume, consultations are reviewed the same day by a GPhC-registered Independent Prescriber, not routed through automated software. The process covers your medical history, current medicines, weight and identity verification before any prescription is considered. For people weighing up whether the NHS or a private route makes more sense for them, this page on whether semaglutide is available on the NHS covers the commissioning detail more fully. If you're ready to explore whether you're clinically suitable, checking your eligibility starts with a free consultation.

What Wegovy actually involves as a treatment

Semaglutide (Wegovy) is a GLP-1 receptor agonist injected once weekly using a pre-filled pen. Treatment begins at a low dose and is titrated upward by your prescriber over several months, with 2.4 mg as the standard maintenance dose. In April 2026, the MHRA also approved a dedicated single-dose 7.2 mg pen for adults with a BMI of 30 or above, representing the highest available maintenance dose, and this page on when Wegovy is available on the NHS explains where the commissioning of newer doses currently stands. The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average weight reduction over 68 weeks at 2.4 mg alongside lifestyle changes, a figure cited by NICE in its assessment.

Side effects are mostly gastrointestinal: nausea, loose stools, constipation and indigestion are common, particularly around dose increases, and usually settle as the body adjusts. Keeping the pen in the fridge door and injecting at the same time each week helps build the habit without disruption. For a full overview of what treatment involves day-to-day, the Wegovy treatment page covers the schedule, storage and what to expect. Treatment for weight management is not recommended during pregnancy, while breastfeeding, or when trying to conceive, and is not licensed for under-18s. If you are unsure whether you would qualify through the health service, this guide to whether Wegovy is available on the NHS explains the current funding picture and what it means in practice.